Search Results
Your search for 3 matches 15507 pages
Showing 14301 - 14350Benefit of Maintenance Bevacizumab-Erlotinib vs Bevacizumab After Bevacizumab-Based Induction Therapy in Metastatic Colorectal Cancer
As reported by Tournigand et al in The Lancet Oncology, final analysis of the phase III GERCOR DREAM (OPTIMOX3) trial suggested a benefit of maintenance bevacizumab (Avastin)-erlotinib vs bevacizumab after bevacizumab-based induction therapy in patients with previously untreated metastatic...
RSNA 2015: Study Suggests Breast Density Alone Not a Risk Factor for Cancer
Breast density may not be a strong independent factor for breast cancer risk, according to a new study presented (BR267-SD-THA1) by Katavic et al December 2, 2015, at the Annual Meeting of the Radiological Society of North America (RSNA) in Chicago. Prior research has shown an association between...
Study Finds Better Outcome With Melphalan Plus ASCT vs Chemotherapy Plus Lenalidomide Consolidation in Multiple Myeloma
In a phase III trial reported in The Lancet Oncology, Gay et al found that progression-free survival was shorter with lenalidomide (Revlimid) plus chemotherapy vs high-dose melphalan plus autologous stem cell transplantation in transplant-eligible patients with multiple myeloma, with no significant ...
German Phase II Trial Shows Benefit and Increased Toxicity With Addition of Sorafenib to Standard Therapy in Newly Diagnosed AML
In a German phase II trial reported in The Lancet Oncology, Röllig et al found that the addition of sorafenib (Nexavar) to standard therapy improved event-free survival but increased toxicity vs placebo in patients aged ≤ 60 years with newly diagnosed acute myeloid leukemia (AML). Study...
FDA Approves Single-Agent Nivolumab for Previously Untreated BRAF Wild-Type Advanced Melanoma
The U.S. Food and Drug Administration (FDA) today approved the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) as a single agent for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. Clinical Trial Results The approval is based on data...
FDA Approves Necitumumab Combination for Metastatic Squamous NSCLC
The U.S. Food and Drug Administration today approved necitumumab (Portrazza) in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). Necitumumab is not indicated for treatment of nonsquamous NSCLC....
Vigorous Exercise and Healthy Habits May Dramatically Reduce Chance of Lethal Prostate Cancer for Men Over 60
A study that tracked tens of thousands of middle-aged and older men for more than 20 years has found that vigorous exercise and other healthy lifestyle habits may cut their chances of developing a lethal type of prostate cancer by up to 68%. While most prostate cancers are clinically indolent, a...
Chitosane-Based Injectable Biogel Delivers Anticancer Agents Directly Into Tumors in Laboratory Setting
A new, injectable “biogel” is effective in delivering anticancer agents directly into cancerous tumors and killing them, according to a study published by Monette et al in Biomaterials. The technology was developed by researchers at the University of Montreal Hospital Research Centre...
Study Advances Potential Test to Distinguish Precancerous Pancreatic Cysts From Harmless Ones
In a retrospective analysis of data from 130 patients with pancreatic cysts, scientists at Johns Hopkins have used gene-based tests and a fixed set of clinical criteria to more accurately distinguish precancerous cysts from those less likely to do harm. The findings may eventually help some...
Healthy Diet May Reduce Risk of Ovarian Cancer in African American Women
A healthy diet may reduce the risk of ovarian cancer in African American women, according to data presented at the Eighth American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held November...
Disparities in Colorectal Cancer Death Rates Take a Large Economic Toll
Disparities in colorectal cancer death rates take a large toll on the national economy, with poorer, less-educated communities bearing the greatest burden, according to data presented at the Eighth American Association for Cancer Research (AACR) Conference on the Science of Cancer Health...
FDA Approves Daratumumab for Patients With Previously Treated Multiple Myeloma
Today the U.S. Food and Drug Administration granted accelerated approval for daratumumab (Darzalex) to treat patients with multiple myeloma who have received at least three prior treatments, including a proteasome inhibitor and an immunomodulatory agent, or who are double-refractory to a proteasome ...
Single-Institution Experience Indicates Improved Outcomes With Higher Radiotherapy Doses in Inoperable Intrahepatic Cholangiocarcinoma
In a single-institution retrospective analysis reported in the Journal of Clinical Oncology, Tao et al found that use of higher radiotherapy doses was associated with prolonged local control and overall survival in patients with inoperable intrahepatic cholangiocarcinoma. Overall survival was...
Investigational NAE Inhibitor Pevonedistat Shows Potential Activity in Patients With Relapsed/Refractory Lymphoma
A phase I study evaluating the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma has found...
Good Outcomes With Intensive, Interval-Compressed Chemotherapy and Irinotecan as Radiosensitizer in High-Risk Rhabdomyosarcoma
As reported in the Journal of Clinical Oncology by Weigel et al in the Children’s Oncology Group, a strategy of dose intensification and interval compression, use of the most active agents determined in phase II window studies, and use of irinotecan as a radiation sensitizer has been found to ...
Improved Outcomes With Modified Docetaxel, Cisplatin, and 5-FU vs Standard Regimen Plus Growth Factor Support in Metastatic Gastric Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Shah et al in the U.S. Gastric Cancer Consortium found that a modified regimen of docetaxel, cisplatin, and fluorouracil (5-FU) (mDCF) improved toxicity and survival vs a standard DCF regimen plus growth factor support as first-line...
Liquid Biopsy Promotes Precision Medicine by Tracking Patient's Cancer
A team of researchers, including scientists from the Translational Genomics Research Institute (TGen), has reported that analyzing circulating tumor DNA (ctDNA) can track how a patient's cancer evolves and responds to treatment. In a study published in Nature Communications, Muhammed Murtaza, PhD, ...
Increasing Use of Preoperative Breast MRI Linked to Increased Postdiagnostic Imaging and Biopsy, Mastectomy, and Surgery Delay
In a Canadian population-based study reported in JAMA Oncology, Arnaout et al found that breast magnetic resonance imaging (MRI) is increasingly used in preoperative evaluation of women with breast cancer and that its use is associated with increased likelihood of confirmatory breast imaging,...
PARP Inhibitor Olaparib Produces High Response Rate in Metastatic Prostate Cancer With DNA Repair Defects
In a phase II trial reported in The New England Journal of Medicine, Mateo et al found that the PARP inhibitor olaparib (Lynparza) produced a high response rate in patients with previously treated metastatic castration-resistant prostate cancer with tumors exhibiting defects in DNA repair genes....
Chemotherapy-Induced Hearing Loss Affects Cognition in Pediatric Brain Tumor Survivors
More children are surviving malignant brain tumors than in the past, thanks to the use of intense treatments using platinum-based chemotherapy (cisplatin and high-dose carboplatin). Unfortunately, the therapy has a known side effect of permanent hearing loss, resulting from damage to the inner ear. ...
No Difference in Overall Survival, Poorer Relapse-Free Survival With Adjuvant Intermittent vs High-Dose Interferon Alfa-2b in Stage III Melanoma
The final analysis of a European Dermatologic Cooperative Oncology Group phase III trial, reported in the Journal of Clinical Oncology by Mohr et al, showed that adjuvant intermittent vs standard high-dose intravenous interferon alfa-2b was associated with no difference in overall survival but...
Dexamethasone Reduces Pain Flare After Palliative Radiotherapy for Bone Metastases
In a Canadian phase III trial reported in The Lancet Oncology, Chow et al found that prophylactic dexamethasone reduced the incidence of radiation-induced pain flare compared with placebo in patients receiving palliative radiotherapy for bone metastases. Study Details In this double-blind trial,...
Lenalidomide Plus Rituximab Appears Promising as First-Line Therapy for Mantle Cell Lymphoma
Mantle cell lymphoma, which is characterized by CD5-positive, CD23-negative follicular mantle B cells with t(11:14)(q13;q32) translocation and cyclin D1 overexpression, is generally incurable and associated with a median survival of between 4 and 5 years. Although front-line treatment for mantle...
No Reduction in Recurrent Colorectal Adenomas With Vitamin D and Calcium Supplementation
In a trial reported in The New England Journal of Medicine, Baron et al found that daily vitamin D and calcium supplementation did not reduce recurrence of colorectal adenomas in patients with recently diagnosed adenomas and no known polyps remaining after complete colonoscopy. Study Details In...
No Significant Survival Improvement With Etirinotecan Pegol vs Physician’s Choice in Heavily Pretreated Advanced Breast Cancer
In the phase III BEACON trial reported in The Lancet Oncology, Perez et al found that etirinotecan pegol was not associated with a significant increase in overall survival compared with physician’s choice of treatment in women with locally recurrent or metastatic breast cancer previously...
Researchers Discover SEC23B, Gene Associated With Cowden Syndrome, Contributes to Thyroid Cancer Risk
Cleveland Clinic researchers have discovered a gene associated with Cowden syndrome, an inherited condition that carries high risks of thyroid, breast, and other cancers, and a subset of noninherited thyroid cancers. These findings were published by Yehia et al in the American Journal of Human...
Stool DNA Test Accurate in Screening for Colorectal Cancer in Alaska Native People
Cologuard stool DNA testing for colorectal cancer was found to be an accurate noninvasive screening option for Alaska Native people, a population with one of the world's highest rates of colorectal cancer, concluded researchers from the Alaska Native Tribal Health Consortium and Mayo Clinic. The...
Chemoradiotherapy Survival Benefit in Elderly Patients With Limited-Stage SCLC
In a population-based study reported in the Journal of Clinical Oncology, Corso et al found that chemoradiotherapy was associated with an overall survival benefit vs chemotherapy in elderly patients with limited-stage small cell lung cancer (SCLC). Study Details The study involved National Cancer ...
Reduced Relapse but No Quality-of-Life Benefit With ATRA/Arsenic Trioxide vs ATRA/Idarubicin in Acute Promyelocytic Leukemia
In a UK-based phase III trial (AML17) reported in The Lancet Oncology, Burnett et al found that a chemotherapy-free regimen of arsenic trioxide plus all-trans retinoic acid (ATRA) did not improve quality of life, the primary endpoint, vs ATRA plus idarubicin in patients with acute promyelocytic...
FDA Approves Adjuvant Ipilimumab to Reduce the Risk of Melanoma Returning After Surgery
The U.S. Food and Drug Administration has expanded the approved use of ipilimumab (Yervoy) to include a new use as adjuvant therapy for patients who have cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm and have undergone complete resection, including total...
Telotristat Etiprate Shows Clinical Benefit in Treating Carcinoid Syndrome in Cancer Patients When Added to Standard of Care
Lexicon Pharmaceuticals, Inc's telotristat etiprate was shown to have clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog therapy, the current standard of care, according to data from the phase III TELESTAR study presented...
FDA Approves Talimogene Laherparepvec for Unresectable Recurrent Melanoma
The U.S. Food and Drug Administration (FDA) has approved the biologics license application for talimogene laherparepvec (Imlygic), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma...
Second-Line Lenvatinib Plus Everolimus Improves Progression-Free Survival vs Everolimus in Metastatic Renal Cell Carcinoma in Phase II Trial
In a phase II trial reported in The Lancet Oncology, Motzer et al found that the combination of the multi–tyrosine kinase inhibitor lenvatinib (Lenvima) plus the mTOR inhibitor everolimus (Afinitor) significantly improved progression-free survival vs everolimus alone in patients with...
Study Finds Tumor-Derived Exosomes May Predict Patients Likely to Develop Cancer Metastasis
Researchers investigating the role of exosomes, comprised of tumor-derived proteins, in the development of cancer metastasis have found that an “exosomal protein signature” could identify patients at risk for metastasis. The research also indicates that integrin expression profiles of...
Good Outcome With Neoadjuvant Chemoradiation and Local Excision in Clinical T2,N0 Distal Rectal Cancer
In a multi-institutional phase II trial (ACOSOG Z6041) reported in The Lancet Oncology, Garcia-Aguilar et al found that neoadjuvant chemoradiotherapy and local excision was associated with an acceptable disease-free survival rate, albeit not so high as anticipated, in patients with clinical stage...
ASCO Calls for Comprehensive Payment Reform to Address Issue of Site Neutrality
ASCO has called for comprehensive physician payment reform to support the full scope of services required by patients with cancer, rather than jeopardizing patient outcomes by reducing the available resources in a particular cancer care setting in an effort to achieve "site neutrality" in...
ASTRO 2015: The Addition of 24 Months of Daily Antiandrogen Therapy Improves Overall Survival Following Recurrence After a Radical Prostatectomy
Prostate cancer patients who face recurrence after radical prostatectomy have better overall survival rates with a combination of salvage radiation therapy and 24 months of antiandrogen therapy than with radiation therapy alone, according to research (Abstract LBA5) presented by Shipley et al on...
ASTRO 2015: A Shorter Radiation Therapy Schedule Can Be as Effective as a Conventional Schedule for Men With Low-Risk Prostate Cancer
Hypofractionated radiation therapy results in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research (Abstract LBA6) presented by Lee et al October 19, 2015, at the American Society for Radiation Oncology...
ASTRO 2015: Pediatric Patients With Ependymoma Have Favorable Outcomes With Immediate Postsurgical Radiation Therapy
Outcomes for pediatric patients as young as 12 months old with ependymoma who are treated with immediate postoperative radiation therapy are favorable and consistent, based upon tumor surgical resection and tumor grade, according to research presented by Merchant et al (Abstract 1) on October...
Addition of Cediranib to Carboplatin/Paclitaxel Improves Progression-Free Survival in Metastatic/Recurrent Cervical Cancer in UK Phase II Trial
In a UK phase II trial reported in The Lancet Oncology, Symonds et al found that the addition of the investigational VEGFR1, -2, and -3 inhibitor cediranib to carboplatin/paclitaxel improved progression-free survival in patients with metastatic or relapsed cervical cancer. The addition of cediranib ...
ASTRO 2015: Hypofractionated Radiation Therapy May Be an Acceptable Treatment for Some Patients With Localized Prostate Cancer
Long-term patient-reported outcomes indicate that for some men with localized prostate cancer, hypofractionated intensity-modulated radiation therapy (IMRT) may be a reasonable treatment option and result in similar quality-of-life outcomes, compared to conventional radiation therapy, according to...
ASTRO 2015: Patients With Intermediate-Risk Meningiomas Who Receive Postoperative Radiotherapy Have a 96% 3-Year Progression-Free Survival
Patients with intermediate meningiomas treated with radiation therapy after surgery experienced a 96% 3-year progression-free survival rate and had minimal adverse events, according to research presented by Rogers et al October 21, 2015, at the American Society for Radiation Oncology’s...
ASTRO 2015: Involved-Field Irradiation for Locally Advanced Esophageal Cancer Reduces Toxicity Without Increasing Locoregional Lymph Node Recurrence
For patients with locally advanced esophageal cancer that has spread to the lymph nodes, radiation therapy that targets only the involved lymph node regions results in less toxicity without causing a statistically significant difference in locoregional lymph node recurrence, distant failure, and...
ASTRO 2015: Coordinated Radiation Therapy and Palliative Care Based on Patient Feedback Lead to Better Quality of Life, Reduced Health-Care Costs
A collaborative, patient-reported outcome–based approach by palliative care and radiation oncology teams results in better outpatient symptom management and a decrease in end-of-life hospitalizations and costs for late-stage cancer patients, according to research presented by Read et al...
ASTRO 2015: Image-Guided Intensity-Modulated Radiation Therapy Reduces Bowel Side Effects in Cervical Cancer Patients
For cervical cancer patients undergoing postsurgical radiation therapy, image-guided intensity-modulated radiation therapy (IMRT) resulted in a 14% reduction in moderate-to-severe bowel side effects when compared to conventional three-dimensional conformal radiation therapy (3D CRT), according to...
ASTRO 2015: Frequent Post-Treatment Follow-up by Advance Practice Nurses Improves Care for Patients With High-Risk Head and Neck Cancer
For high-risk patients who receive chemoradiotherapy for head and neck cancer, frequent follow-up appointments conducted by advance practice nurses (APNs) in a clinical outpatient setting allowed for more intensive symptom management, resulting in fewer post-treatment emergency room visits and...
Study Compares Maintenance Strategies After First-Line Oxaliplatin/Fluoropyrimidine/Bevacizumab in Patients With Metastatic Colorectal Cancer
In a German noninferiority phase III trial (AIO 0207) reported in The Lancet Oncology, Hegewisch-Becker et al found that maintenance treatment with bevacizumab (Avastin) was noninferior to a fluoropyrimidine plus bevacizumab in time to maintenance strategy failure following first-line treatment...
ASTRO 2015: Reduced-Intensity Chemoradiotherapy May Be as Effective as Current Standard for Patients With HPV-Related Oropharynx Cancer
For some patients with human papillomavirus (HPV)-related cancer of the tonsils and tongue, reduced-intensity radiation therapy and chemotherapy may be as effective as standard-dose radiation and chemotherapy, and result in fewer acute side effects, according to research presented by Chera et al...
ASTRO 2015: Subset of Patients With Metastatic Melanoma Achieves Clinical Benefit From Combination of Immunotherapy and Radiation Therapy
Immunotherapy combined with palliative radiation therapy for a subset of patients with metastatic melanoma reduces the growth and spread of the cancer, according to research presented by Hiniker et al (Abstract 215) on October 20, 2015 at the American Society for Radiation Oncology’s...
Extended RAS Mutation Testing in Metastatic Colorectal Cancer to Predict Response to Anti-EGFR Antibody Therapy
As reported in the Journal of Clinical Oncology by Allegra et al, ASCO has issued a provisional clinical opinion (PCO) update on extended RAS mutation testing in metastatic colorectal cancer to predict response to anti-EGFR monoclonal antibody treatment. The update revises a 2009 PCO and is based...
